- Tenofovir Alafenamide is an anti-hepaciviral and antiretroviral medication.
- In HIV-infected patients, Tafnat not used alone and can be combined with some other antiretroviral medications such as Emtricitabine, cobicistat or darunavir.
- At first, Tafnat belongs to the antiretroviral (nucleoside reverse transcriptase inhibitor), now Tafnat has an antihepaciviral property that is used against hepatitis B viral infection
USES
- Prior use of the Tafnat tablet , used in HIV-1 infection The Tafnat tablet is also indicated for the treatment of viral hepatitis B infection, by reducing the progression of the Tafnat virus used in chronic hepatitis B infection, it is not curable but can prevent viral transmission
CATEGORY
- Antiretroviral drug
- Antihepaciviral drug
TAFNAT TABLET
- The usual dose of Tafnat tablet is, a tablet containing 25 mg of Tenofovir Alafenamide should be taken as a single dose. Tafnat tablet should be administered with food. Recommended Before starting therapy: patients should examine HIV-1 infection to recommend the combination of other antiretroviral drugs in patients with HIV-1 positive.
WORKS
- Tafnat – Tenofovir Alafenamide (TAF) TAF is a prodrug of tenofovir (original drug) At first, TAF penetrates liver cells because it has a capacity permeable to lipophilic cells.
- After entering the cells, TAF is subjected to hydrolysis by the use of carboxylesterase-1 and is formed as tenofovir.
- Tenofovir participates in intracellular metabolism, which is phosphorylated in tenofovir triphosphate.
- Tenofovir triphosphate is considered an active metabolite that has antiviral properties and is integrated into viral DNA by the reverse transcriptase enzyme of hepatitis B and leads to inhibit viral production, resulting in the termination of the viral chain.
How the body works for Tafnat tablets
- After an oral administration, the absorption of the Tafnat tablet occurs rapidly. The maximum plasma time occurs within 0.48 hours. The effect of food while taking the Tafnat tablet is included as; With high-fat food, the effect of Tenofovir Alafenamide is 1.65 Tafnat is highly bound to human plasma proteins almost 80% The blood plasma ration is 1.0 Metabolism of Tenofovir Alafenamide is produced with the help of cathepsin A, carboxylesterase- 1 The half-life period of Tenofovir Alafenamide is 0.51 hours Excretion occurs through urine <1%; stool 31.7%
WARNING AND CAUTION
- After cessation of hepatitis B therapy by using the Tafnat tablet , it concluded in a severe and severe worsening of hepatitis B infection. To avoid this adverse condition in patients, liver function should be observed frequently.
- Exposure of reinforcement of HIV-1 antagonism in patients infected with HBV / HIV-1 In patients infected with HIV, combined therapy is suggested to prevent this condition in coinfected patients. Check the HIV antibody in all patients infected with HBV before starting therapy.
- New onset and worsening of renal damage Patient with low renal function capacity, discontinue Tafnat tablet therapy immediately and control serum phosphorus, serum creatinine, urinary protein, urine glucose and creatinine clearance frequently
- Lactic acidosis or severe hepatomegaly with steatosis If this condition occurred in patients, immediately discontinue treatment and provide safety measures.
DRUG INTERACTION
- Tafnat combined with strong inhibitors of P-gp or BCRP, results as an alteration of the absorption of the inducers of Tenofovir Alafenamide P-gp or BCRP, combined with the Tafnat tablet leads to the loss of the therapeutic effect of Tafnat Tafnat with moderate inhibitors of P-gp or BCRP as Therefore, the increased absorption produces plasma concentrations of Tenofovir Alafenamide Tafnat in tablets combined with anticonvulsants (phenytoin, carbamazepine or phenobarbital), antimycobacterials (rifampicin, rifapentin or rifabutin) or herbal products (St herb Johns) that cause depletion in the effect of concentration. from Tafnat
MISSED DOSE
- Once the missed dose has occurred, the patient should consult a doctor and follow the instructions.
- Otherwise, the missed dose should be omitted and proceed from the regular dosing schedule.
OVERDOSE
In overdose conditions, follow two steps:
- Examine the toxicity deposit and the symptoms due to overdose
- Hemodialysis, a method involved in the eradication of Tafnat overdose with a separation coefficient of 54%.
SIDE EFFECTS
Important adverse effects;
- Lactic acidosis or severe hepatomegaly with steatosis
- Reactivation of worsening hepatitis B viral infection after therapy
- Kidney damage occurs.
- Some of the undesirable effects;
- Headache
- Fatigue
- Tos
- Nausea
- Back pain
- Abdominal pain
- Bone mineral density reduction.
- Glucosuria
- Elevation of creatine kinase
- Amylase lipase elevated.
CONTACT DETAILS
Phone: + 91-9987711567
Email: applepharmaceutical@gmail.com
Email: info@myapplepharma.com
katherine 